Journal
IMMUNOLOGIC RESEARCH
Volume 69, Issue 2, Pages 162-175Publisher
SPRINGER
DOI: 10.1007/s12026-021-09176-6
Keywords
Pulmonary edema; Dexmedetomidine; ENaC; AFC; PI3K; Akt; Nedd4-2 signaling pathway
Categories
Funding
- Technical Research and Development Fund of Shenzhen [JCYJ20160422142317026]
- Scientific Research Project of Shenzhen Health and Family Planning System [SZFZ2018032]
- Shenzhen Key Medical Discipline Construction Fund [SZXK044]
- Sanming Project of Medicine in Shenzhen [SZSM202011021]
Ask authors/readers for more resources
Dex alleviates pulmonary edema in LPS-induced ALI by promoting AFC and suppressing inflammatory response. The mechanism involves upregulating ENaC expression through the PI3K/Akt/Nedd4-2 signaling pathway, with the protective role of Dex being PI3K-dependent.
Dexmedetomidine (Dex), a highly selective alpha(2)-adrenergic receptor (alpha(2)AR) agonist, has an anti-inflammatory property and can alleviate pulmonary edema in lipopolysaccharide (LPS)-induced acute lung injury (ALI), but the mechanism is still unclear. In this study, we attempted to investigate the effect of Dex on alveolar epithelial sodium channel (ENaC) in the modulation of alveolar fluid clearance (AFC) and the underlying mechanism. Lipopolysaccharide (LPS) was used to induce acute lung injury (ALI) in rats and alveolar epithelial cell injury in A549 cells. In vivo, Dex markedly reduced pulmonary edema induced by LPS through promoting AFC, prevented LPS-induced downregulation of alpha-, beta-, and gamma-ENaC expression, attenuated inflammatory cell infiltration in lung tissue, reduced the concentrations of TNF-alpha, IL-1 beta, and IL-6, and increased concentrations of IL-10 in bronchoalveolar lavage fluid (BALF). In A549 cells stimulated with LPS, Dex attenuated LPS-mediated cell injury and the downregulation of alpha-, beta-, and gamma-ENaC expression. However, all of these effects were blocked by the PI3K inhibitor LY294002, suggesting that the protective role of Dex is PI3K-dependent. Additionally, Dex increased the expression of phosphorylated Akt and reduced the expression of Nedd4-2, while LY294002 reversed the effect of Dex in vivo and in vitro. Furthermore, insulin-like growth factor (IGF)-1, a PI3K agonists, promoted the expression of phosphorylated Akt and reduced the expression of Nedd4-2 in LPS-stimulated A549 cells, indicating that Dex worked through PI3K, and Akt and Nedd4-2 are downstream of PI3K. In conclusion, Dex alleviates pulmonary edema by suppressing inflammatory response in LPS-induced ALI, and the mechanism is partly related to the upregulation of ENaC expression via the PI3K/Akt/Nedd4-2 signaling pathway.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available